CAMBRIDGE, Mass. & CARLSBAD, Calif.-Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for ...

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

All Filling and Finishing for U.S. Market Transferred Out of Allston Plant CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) announced today that the company has ended fill/finish ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme Corporation (Nasdaq: GENZ) announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme Corporation (Nasdaq: GENZ) announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S.

Genzyme Corp. and Integrated Genetics, which both launched themselves in 1981, became one in 1989, and since then Genzyme has used IG’s 51 New York Ave. location in Framingham to keep expanding.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Dana Alexander, program director for Genzyme, shows off the company's new $170 million manufacturing facility in Framingham during a tour of the site on Tuesday. BRANDON BUTLER While Cambridge-based ...